HMIC is an American intellectual-property company developing auditable infrastructure for human and AI collaboration. Our architecture produces the provenance, traceability, and reconstructability that existing regulatory frameworks already require, so compliance does not have to catch up to the technology.
Modern artificial intelligence is opaque by default. Its outputs are probabilistic, its internals are inaccessible, and its reasoning cannot be reconstructed after the fact. These properties are incompatible with the frameworks that govern medicine, finance, aviation, and every other regulated domain the United States has built over the past century.
The dominant response has been to ask regulators, and the institutions they oversee, to absorb new vocabulary, new risk models, and new evaluation methods. This is slow, expensive, and unevenly applied.
HMIC's core technology, SubC, is a human and machine interface in which every exchange is compressed through a shared, inspectable state. The artifacts the architecture produces, including codebook versions, evidence ledgers, and provenance trails, are the same artifacts that 21 CFR Part 11, GxP, and ICH guidelines already require of any validated system.
An auditor does not need to understand the model. They need to verify the record. SubC produces the record.
Every output is traceable to a versioned state of the shared codebook. Reconstruction of any prior decision is a lookup, not a forensic exercise.
The architecture is designed to operate on premises, air-gapped, or within controlled enclaves. No mandatory foreign cloud dependency. No mandatory foundation-model intermediary.
Access and attribution are anchored in verifiable signing primitives, including biometric enrollment and hardware key attestation, rather than revocable software credentials.
The audit trail is not a logging subsystem bolted to the application. The audit trail is the application.
HMIC's architecture was developed with explicit reference to the United States regulatory corpus. Each primitive below maps to requirements already familiar to compliance officers, quality assurance directors, and federal examiners.
HMIC has filed four United States Provisional Patent Applications with the United States Patent and Trademark Office, representing the foundational coverage of the SubC architecture. Non-provisional conversion is calendared for February 2027. International prosecution under the Patent Cooperation Treaty is under evaluation for the fourth-quarter 2026 window.
Methods for amplifying effective context across human and machine exchanges without expansion of transmitted payload.
Measurement protocols for characterizing compression achieved across bidirectional human and machine communication channels.
Systems and methods for composing inference across heterogeneous model tiers with provenance preservation.
Authentication architectures combining biometric, hardware-signing, and contextual-attestation primitives.
The United States became the world leader in science and engineering because public research, academic inquiry, and private enterprise reinforced one another. HMIC is built in that tradition.
We believe in public education. We believe in open academic inquiry. We believe that the hardest problems in human and AI collaboration will be solved by synergy across institutions, not by any single firm operating alone.
HMIC welcomes collaboration with academic laboratories, public research institutions, teaching hospitals, federally funded centers, and student researchers. We are open to joint studies, sponsored research arrangements, shared-authorship publications, curriculum partnerships, and internship pipelines.
For academic and public-research inquiries, please contact us directly. We respond to student and faculty inquiries with the same attention we give commercial ones.
HMIC's commercial model is built on characterized compression, the licensing of measured, auditable architecture rather than the sale of inference capacity. This model is compatible with the procurement norms of United States regulated industries and of federal acquisition authorities.
Our current pilot deployments focus on bioscience applications, in cooperation with domestic partners who share the premise that regulatory legibility is a feature, not an overhead.
Inquiries from United States government agencies, federally funded research programs, and domestic life-science institutions are welcomed.